The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk
Surgical site infections and antimicrobial resistance remain major challenges globally
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Subscribe To Our Newsletter & Stay Updated